Organism: Homo sapiens
Gene: 38949_at
Selected probe(set): 210038_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38949_at (210038_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):5.140154
Number of Samples:2 / 2

Experimental	expO stomach cancer study 1 (gastrointestinal stromal tumor; primary)
	Primary tumor tissue samples obtained from the stomach of patients with gastrointestinal stromal tumor.
Control	expO stomach cancer study 1 (Signet ring cell carcinoma; primary)
	Primary tumor tissue samples obtained from the stomach of patients with Signet ring cell carcinoma.

Relative Expression (log2-ratio):4.966792
Number of Samples:2 / 3

Experimental	expO stomach cancer study 1 (gastrointestinal stromal tumor; primary)
	Primary tumor tissue samples obtained from the stomach of patients with gastrointestinal stromal tumor.
Control	expO stomach cancer study 1 (adenocarcinoma, NOS; primary)
	Primary tumor tissue samples obtained from the stomach of patients with adenocarcinoma (NOS).

Relative Expression (log2-ratio):4.718325
Number of Samples:3 / 3

Experimental	HIF-1a/HIF-2a depletion study 1 (hypoxia; HK2)
	Proximal tubule epithelial cell line HK-2 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with hypoxia (20% O2). HK-2 cells were cultured in DMEM/F-12 supplemented with 10% fetal calf serum (FCS), 1% ITS, hydrocortisone, and antibiotics. The cells were incubated at 37 °C.
Control	HIF-1a/HIF-2a depletion study 1 (normoxia; AB81)
	Human podocyte cells AB81 with shRNA-mediated stable knock-down of HIF-1a and HIF-2a (Hypoxia-inducible factor 1-alpha and Hypoxia-inducible factor 2-alpha) 24 hours after treatment with normoxia (20% O2). Conditionally immortalized human podocytes AB81 were cultured under permissive conditions (33 °C) in RPMI-1640 supplemented with 10% FBS, antibiotics, and 1% ITS. Differentiation was induced by thermoshift to 37 °C in 6-well plates.

Relative Expression (log2-ratio):-4.297365
Number of Samples:12 / 6

Experimental	retina pigment epithelium study 2 (fetal)
	Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control	retina pigment epithelium study 1 (fetal)
	Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

Relative Expression (log2-ratio):-3.897358
Number of Samples:17 / 29

Experimental	precursor-B-ALL study 3 (hyperdiploid)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.7664194
Number of Samples:4 / 29

Experimental	precursor-B-ALL study 3 (BCR-ABL)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

Relative Expression (log2-ratio):-3.6208973
Number of Samples:4 / 4

Experimental	stem cell differentiation study 59 (iDRG; 12d)
	Immature dorsal root ganglia neurons (iDRGs) obtained by differentiation of WA09 embryonic stem cells. WA09 cells were differentiated for 8 days and subsequently cryopreserved. After thawing, cells were further differentiated for 4 days. Further details are described in the paper.
Control	normal embryonic stem cell sample (WA09)
	Undifferentiated WA09 embryonic stem cell samples.

Relative Expression (log2-ratio):-3.6131983
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal T-cell; 20uM)
	MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-3.5748768
Number of Samples:2 / 3

Experimental	stem cell differentiation study 41 (T3pi)
	Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control	undifferentiated hES-T3 cell sample
	Undifferentiated human embryonic stem cells T3.

Relative Expression (log2-ratio):-3.5254364
Number of Samples:6 / 29

Experimental	precursor-B-ALL study 3 (PAX5-rearranged)
	Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [dic(9;20)(p11-13;q11) )/PAX5 rearranged]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control	T-ALL study 3
	Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).